Bolt Biotherapeutics to Participate in Upcoming February Conferences

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology firm, recently announced upcoming presentations at two key conferences in February 2022. The first is the Guggenheim 2022 Oncology Virtual Conference on February 9 at 10:00 a.m. PT, followed by the SVB Leerink Global Healthcare Conference on February 16 at 2:00 p.m. PT. Both events will feature fireside chats, available for live streaming on Bolt's website, with archived replays accessible for 90 days post-event.

Bolt focuses on innovative immuno-oncology agents, particularly its lead candidate, BDC-1001, targeting HER2-expressing tumors.

REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present at two upcoming conferences in February:

• Guggenheim 2022 Oncology Virtual Conference
  Fireside chat on Wednesday, Feb. 9, at 10:00 a.m. PT (1:00 p.m. ET)
  
  
• Virtual 11^th Annual SVB Leerink Global Healthcare Conference 2022
  Fireside chat on Wednesday, Feb. 16, at 2:00 p.m. PT (5:00 p.m. ET)

A live webcast of these fireside chats will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 90 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugates (ISACs) are designed to target tumor cells for elimination by myeloid cells, which then activates the myeloid cells to recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products. 

Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

Maggie Beller or David Schull
Russo Partners, LLC
646-942-5631
maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com

FAQ

What presentations will Bolt Biotherapeutics hold in February 2022?

Bolt Biotherapeutics will present at the Guggenheim 2022 Oncology Virtual Conference on February 9 and the SVB Leerink Global Healthcare Conference on February 16, 2022.

What is the schedule for Bolt Biotherapeutics' events in February?

The schedule includes the Guggenheim conference on February 9 at 10:00 a.m. PT and the SVB Leerink conference on February 16 at 2:00 p.m. PT.

Where can I watch Bolt Biotherapeutics' conference presentations?

The live webcasts of the presentations can be streamed on Bolt Biotherapeutics' Events and Presentations page on their website.

What is Bolt Biotherapeutics' lead candidate?

Bolt Biotherapeutics' lead candidate is BDC-1001, designed for targeting HER2-expressing solid tumors.

How long will the archived presentations from Bolt Biotherapeutics be available?

The archived presentations will be available for 90 days following each event.